Does the media favor PRME or BEAM?

In the previous week, Beam Therapeutics had 6 more articles in the media than Prime Medicine. MarketBeat recorded 8 mentions for Beam Therapeutics and 2 mentions for Prime Medicine. Beam Therapeutics' average media sentiment score of 0.92 beat Prime Medicine's score of 0.00 indicating that Beam Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Beam Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PRME or NTLA?

In the previous week, Intellia Therapeutics had 2 more articles in the media than Prime Medicine. MarketBeat recorded 4 mentions for Intellia Therapeutics and 2 mentions for Prime Medicine. Intellia Therapeutics' average media sentiment score of 0.42 beat Prime Medicine's score of 0.00 indicating that Intellia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Intellia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor TRVI or PRME?

In the previous week, Trevi Therapeutics had 1 more articles in the media than Prime Medicine. MarketBeat recorded 3 mentions for Trevi Therapeutics and 2 mentions for Prime Medicine. Trevi Therapeutics' average media sentiment score of 0.21 beat Prime Medicine's score of 0.00 indicating that Trevi Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prime Medicine 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PRME or PHVS more profitable?

Pharvaris has a net margin of 0.00% compared to Prime Medicine's net margin of -4,917.55%. Pharvaris' return on equity of -67.56% beat Prime Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Prime Medicine -4,917.55% -188.82% -60.97% Pharvaris N/A -67.56% -61.13%

Does the media refer more to PRME or PHVS?

In the previous week, Pharvaris had 3 more articles in the media than Prime Medicine. MarketBeat recorded 5 mentions for Pharvaris and 2 mentions for Prime Medicine. Pharvaris' average media sentiment score of 0.39 beat Prime Medicine's score of 0.00 indicating that Pharvaris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pharvaris 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to PRME or AUPH?

In the previous week, Prime Medicine had 1 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 2 mentions for Prime Medicine and 1 mentions for Aurinia Pharmaceuticals. Prime Medicine's average media sentiment score of 0.00 equaled Aurinia Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aurinia Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Prime Medicine (PRME) Competitors

$3.37 +0.14 (+4.33%)

Closing price 06/22/2026 04:00 PM Eastern

Extended Trading

$3.32 -0.06 (-1.63%)

As of 04:11 AM Eastern

Compare

PRME vs. BEAM, NTLA, TRVI, PHVS, and AUPH

Should you buy Prime Medicine stock or one of its competitors? MarketBeat compares Prime Medicine with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Prime Medicine include Beam Therapeutics (BEAM), Intellia Therapeutics (NTLA), Trevi Therapeutics (TRVI), Pharvaris (PHVS), and Aurinia Pharmaceuticals (AUPH). These companies are all part of the "pharmaceutical products" industry.

How does Prime Medicine compare to Beam Therapeutics?

Prime Medicine (NASDAQ:PRME) and Beam Therapeutics (NASDAQ:BEAM) are both pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

Beam Therapeutics has a net margin of -39.66% compared to Prime Medicine's net margin of -4,917.55%. Beam Therapeutics' return on equity of -29.00% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,917.55%	-188.82%	-60.97%
Beam Therapeutics	-39.66%	-29.00%	-22.61%

Prime Medicine currently has a consensus target price of $7.38, suggesting a potential upside of 118.84%. Beam Therapeutics has a consensus target price of $46.83, suggesting a potential upside of 31.81%. Given Prime Medicine's stronger consensus rating and higher possible upside, equities analysts clearly believe Prime Medicine is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71

70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 16.0% of Prime Medicine shares are owned by company insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Prime Medicine has a beta of 2.31, suggesting that its share price is 131% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.25, suggesting that its share price is 125% more volatile than the broader market.

Beam Therapeutics has higher revenue and earnings than Prime Medicine. Beam Therapeutics is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.63M	131.47	-$201.14M	-$1.23	N/A
Beam Therapeutics	$139.74M	26.16	-$79.99M	-$0.68	N/A

In the previous week, Beam Therapeutics had 6 more articles in the media than Prime Medicine. MarketBeat recorded 8 mentions for Beam Therapeutics and 2 mentions for Prime Medicine. Beam Therapeutics' average media sentiment score of 0.92 beat Prime Medicine's score of 0.00 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prime Medicine	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Beam Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Beam Therapeutics beats Prime Medicine on 10 of the 16 factors compared between the two stocks.

How does Prime Medicine compare to Intellia Therapeutics?

Prime Medicine (NASDAQ:PRME) and Intellia Therapeutics (NASDAQ:NTLA) are both pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

Prime Medicine has a beta of 2.31, meaning that its stock price is 131% more volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market.

In the previous week, Intellia Therapeutics had 2 more articles in the media than Prime Medicine. MarketBeat recorded 4 mentions for Intellia Therapeutics and 2 mentions for Prime Medicine. Intellia Therapeutics' average media sentiment score of 0.42 beat Prime Medicine's score of 0.00 indicating that Intellia Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prime Medicine	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Intellia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Prime Medicine currently has a consensus target price of $7.38, indicating a potential upside of 118.84%. Intellia Therapeutics has a consensus target price of $20.46, indicating a potential upside of 29.88%. Given Prime Medicine's stronger consensus rating and higher possible upside, equities analysts clearly believe Prime Medicine is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Intellia Therapeutics	3 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.35

Intellia Therapeutics has a net margin of -597.04% compared to Prime Medicine's net margin of -4,917.55%. Intellia Therapeutics' return on equity of -57.47% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,917.55%	-188.82%	-60.97%
Intellia Therapeutics	-597.04%	-57.47%	-46.24%

70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are owned by institutional investors. 16.0% of Prime Medicine shares are owned by company insiders. Comparatively, 3.5% of Intellia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Prime Medicine has higher earnings, but lower revenue than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.63M	131.47	-$201.14M	-$1.23	N/A
Intellia Therapeutics	$67.67M	32.52	-$412.69M	-$3.54	N/A

Summary

Prime Medicine and Intellia Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Prime Medicine compare to Trevi Therapeutics?

Trevi Therapeutics (NASDAQ:TRVI) and Prime Medicine (NASDAQ:PRME) are both pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Trevi Therapeutics has a net margin of 0.00% compared to Prime Medicine's net margin of -4,917.55%. Trevi Therapeutics' return on equity of -24.53% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-24.53%	-23.37%
Prime Medicine	-4,917.55%	-188.82%	-60.97%

Trevi Therapeutics presently has a consensus target price of $22.90, suggesting a potential upside of 29.31%. Prime Medicine has a consensus target price of $7.38, suggesting a potential upside of 118.84%. Given Prime Medicine's higher probable upside, analysts clearly believe Prime Medicine is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

95.8% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 70.4% of Prime Medicine shares are owned by institutional investors. 18.3% of Trevi Therapeutics shares are owned by insiders. Comparatively, 16.0% of Prime Medicine shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Trevi Therapeutics has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market. Comparatively, Prime Medicine has a beta of 2.31, suggesting that its share price is 131% more volatile than the broader market.

In the previous week, Trevi Therapeutics had 1 more articles in the media than Prime Medicine. MarketBeat recorded 3 mentions for Trevi Therapeutics and 2 mentions for Prime Medicine. Trevi Therapeutics' average media sentiment score of 0.21 beat Prime Medicine's score of 0.00 indicating that Trevi Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevi Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prime Medicine	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Trevi Therapeutics has higher earnings, but lower revenue than Prime Medicine. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A
Prime Medicine	$4.63M	131.47	-$201.14M	-$1.23	N/A

Summary

Trevi Therapeutics beats Prime Medicine on 12 of the 16 factors compared between the two stocks.

How does Prime Medicine compare to Pharvaris?

Prime Medicine (NASDAQ:PRME) and Pharvaris (NASDAQ:PHVS) are both pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

70.4% of Prime Medicine shares are held by institutional investors. 16.0% of Prime Medicine shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Pharvaris has a net margin of 0.00% compared to Prime Medicine's net margin of -4,917.55%. Pharvaris' return on equity of -67.56% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,917.55%	-188.82%	-60.97%
Pharvaris	N/A	-67.56%	-61.13%

Prime Medicine currently has a consensus target price of $7.38, suggesting a potential upside of 118.84%. Pharvaris has a consensus target price of $49.18, suggesting a potential upside of 49.04%. Given Prime Medicine's stronger consensus rating and higher probable upside, equities analysts clearly believe Prime Medicine is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Prime Medicine has a beta of 2.31, indicating that its share price is 131% more volatile than the broader market. Comparatively, Pharvaris has a beta of -2.35, indicating that its share price is 335% less volatile than the broader market.

Pharvaris has lower revenue, but higher earnings than Prime Medicine. Pharvaris is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.63M	131.47	-$201.14M	-$1.23	N/A
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A

In the previous week, Pharvaris had 3 more articles in the media than Prime Medicine. MarketBeat recorded 5 mentions for Pharvaris and 2 mentions for Prime Medicine. Pharvaris' average media sentiment score of 0.39 beat Prime Medicine's score of 0.00 indicating that Pharvaris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prime Medicine	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pharvaris	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Prime Medicine beats Pharvaris on 10 of the 16 factors compared between the two stocks.

How does Prime Medicine compare to Aurinia Pharmaceuticals?

Prime Medicine (NASDAQ:PRME) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

Aurinia Pharmaceuticals has a net margin of 99.97% compared to Prime Medicine's net margin of -4,917.55%. Aurinia Pharmaceuticals' return on equity of 26.62% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,917.55%	-188.82%	-60.97%
Aurinia Pharmaceuticals	99.97%	26.62%	19.65%

70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. 16.0% of Prime Medicine shares are held by insiders. Comparatively, 12.2% of Aurinia Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Aurinia Pharmaceuticals has higher revenue and earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.63M	131.47	-$201.14M	-$1.23	N/A
Aurinia Pharmaceuticals	$298.30M	7.56	$287.20M	$2.17	8.08

In the previous week, Prime Medicine had 1 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 2 mentions for Prime Medicine and 1 mentions for Aurinia Pharmaceuticals. Prime Medicine's average media sentiment score of 0.00 equaled Aurinia Pharmaceuticals'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prime Medicine	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aurinia Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Prime Medicine currently has a consensus price target of $7.38, indicating a potential upside of 118.84%. Aurinia Pharmaceuticals has a consensus price target of $17.25, indicating a potential downside of 1.60%. Given Prime Medicine's stronger consensus rating and higher probable upside, equities analysts clearly believe Prime Medicine is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Aurinia Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Prime Medicine has a beta of 2.31, suggesting that its share price is 131% more volatile than the broader market. Comparatively, Aurinia Pharmaceuticals has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market.

Summary

Prime Medicine beats Aurinia Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Prime Medicine News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRME vs. The Competition

Export

Metric	Prime Medicine	Biological Products, Except Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$583.39M	$469.49M	$4.41B	$12.54B
Dividend Yield	N/A	N/A	10.94%	5.81%
P/E Ratio	-2.74	N/A	21.97	24.33
Price / Sales	131.47	357.30	165.03	112.87
Price / Cash	N/A	N/A	41.09	37.84
Price / Book	5.03	2.76	18.40	6.58
Net Income	-$201.14M	-$81.71M	$115.37M	$336.75M
7 Day Performance	17.42%	8.53%	0.16%	0.15%
1 Month Performance	13.47%	-0.32%	-1.05%	1.47%
1 Year Performance	N/A	N/A	13.76%	33.66%

Prime Medicine Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRME Prime Medicine	1.6317 of 5 stars	$3.37 +4.3%	$7.38 +118.8%	N/A	$583.39M	$4.63M	N/A	N/A	Analyst Forecast Gap Up
BEAM Beam Therapeutics	3.2805 of 5 stars	$30.99 -0.4%	$46.83 +51.1%	+112.0%	$3.19B	$164.01M	N/A	510	Gap Up
NTLA Intellia Therapeutics	3.0755 of 5 stars	$14.55 -2.5%	$20.46 +40.6%	+71.2%	$2.08B	$66.09M	N/A	600
TRVI Trevi Therapeutics	2.5727 of 5 stars	$15.40 +5.0%	$22.90 +48.7%	+197.1%	$2.08B	N/A	N/A	20	Analyst Upgrade High Trading Volume
PHVS Pharvaris	3.3948 of 5 stars	$31.46 -0.3%	$49.18 +56.3%	+83.4%	$2.06B	N/A	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRME) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Prime Medicine (PRME) Competitors

PRME vs. BEAM, NTLA, TRVI, PHVS, and AUPH

How does Prime Medicine compare to Beam Therapeutics?

Summary

How does Prime Medicine compare to Intellia Therapeutics?

Summary

How does Prime Medicine compare to Trevi Therapeutics?

Summary

How does Prime Medicine compare to Pharvaris?

Summary

How does Prime Medicine compare to Aurinia Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRME vs. The Competition

Prime Medicine Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Prime Medicine (PRME) Competitors

PRME vs. BEAM, NTLA, TRVI, PHVS, and AUPH

How does Prime Medicine compare to Beam Therapeutics?

Is PRME or BEAM more profitable?

Do analysts prefer PRME or BEAM?

Do institutionals and insiders hold more shares of PRME or BEAM?

Which has more risk & volatility, PRME or BEAM?

Which has higher earnings & valuation, PRME or BEAM?

Does the media favor PRME or BEAM?

Summary

How does Prime Medicine compare to Intellia Therapeutics?

Which has more volatility & risk, PRME or NTLA?

Does the media prefer PRME or NTLA?

Do analysts recommend PRME or NTLA?

Is PRME or NTLA more profitable?

Do institutionals & insiders have more ownership in PRME or NTLA?

Which has preferable earnings and valuation, PRME or NTLA?

Summary

How does Prime Medicine compare to Trevi Therapeutics?

Is TRVI or PRME more profitable?

Do analysts recommend TRVI or PRME?

Do institutionals & insiders hold more shares of TRVI or PRME?

Which has more volatility & risk, TRVI or PRME?

Does the media favor TRVI or PRME?

Which has preferable earnings and valuation, TRVI or PRME?

Summary

How does Prime Medicine compare to Pharvaris?

Do insiders and institutionals hold more shares of PRME or PHVS?

Is PRME or PHVS more profitable?

Do analysts prefer PRME or PHVS?

Which has more risk and volatility, PRME or PHVS?

Which has higher valuation and earnings, PRME or PHVS?

Does the media refer more to PRME or PHVS?

Summary

How does Prime Medicine compare to Aurinia Pharmaceuticals?

Is PRME or AUPH more profitable?

Do institutionals and insiders have more ownership in PRME or AUPH?

Which has preferable earnings & valuation, PRME or AUPH?

Does the media refer more to PRME or AUPH?

Do analysts recommend PRME or AUPH?

Which has more risk and volatility, PRME or AUPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRME vs. The Competition

Prime Medicine Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools